JT Stratford LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

JT Stratford LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 70.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,128 shares of the biopharmaceutical company’s stock after buying an additional 465 shares during the quarter. JT Stratford LLC’s holdings in Regeneron Pharmaceuticals were worth $712,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its stake in Regeneron Pharmaceuticals by 5.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 556,294 shares of the biopharmaceutical company’s stock valued at $351,311,000 after buying an additional 26,766 shares during the last quarter. General American Investors Co. Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 88.0% in the 4th quarter. General American Investors Co. Inc. now owns 30,076 shares of the biopharmaceutical company’s stock worth $18,994,000 after purchasing an additional 14,075 shares in the last quarter. MAI Capital Management bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $230,000. QCM Cayman Ltd. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $279,000. Finally, Nwam LLC increased its holdings in shares of Regeneron Pharmaceuticals by 134.6% in the 4th quarter. Nwam LLC now owns 1,989 shares of the biopharmaceutical company’s stock worth $1,256,000 after purchasing an additional 1,141 shares in the last quarter. Institutional investors and hedge funds own 83.83% of the company’s stock.

NASDAQ:REGN traded down $1.40 during mid-day trading on Thursday, hitting $657.80. 9,929 shares of the company traded hands, compared to its average volume of 635,080. The stock’s fifty day moving average price is $680.78 and its 200-day moving average price is $645.90. Regeneron Pharmaceuticals, Inc. has a one year low of $492.13 and a one year high of $747.42. The company has a quick ratio of 4.09, a current ratio of 4.76 and a debt-to-equity ratio of 0.14. The firm has a market cap of $71.40 billion, a price-to-earnings ratio of 9.34, a price-to-earnings-growth ratio of 1.25 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported $11.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.37 by $2.12. Regeneron Pharmaceuticals had a return on equity of 50.10% and a net margin of 48.06%. The business had revenue of $2.97 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same quarter in the previous year, the company posted $10.09 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 17.2% on a year-over-year basis. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 40.26 EPS for the current year.

A number of analysts have commented on REGN shares. Oppenheimer reduced their target price on Regeneron Pharmaceuticals from $825.00 to $775.00 and set an “outperform” rating for the company in a report on Tuesday, February 8th. Piper Sandler lifted their target price on Regeneron Pharmaceuticals from $690.00 to $692.00 and gave the stock an “overweight” rating in a report on Friday, February 4th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $754.00 to $728.00 and set a “buy” rating for the company in a report on Tuesday, February 8th. Barclays lifted their price objective on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “overweight” rating in a report on Tuesday, April 12th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $780.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, February 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $724.63.

In other news, CEO Leonard S. Schleifer sold 2,886 shares of the business’s stock in a transaction dated Thursday, March 31st. The stock was sold at an average price of $710.01, for a total value of $2,049,088.86. Following the transaction, the chief executive officer now directly owns 465,922 shares in the company, valued at $330,809,279.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Plew Daniel P. Van sold 6,781 shares of the business’s stock in a transaction dated Wednesday, February 23rd. The shares were sold at an average price of $613.99, for a total value of $4,163,466.19. The disclosure for this sale can be found here. Insiders sold 44,559 shares of company stock worth $30,297,368 over the last 90 days. Company insiders own 11.84% of the company’s stock.

Regeneron Pharmaceuticals Company Profile (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.